News
The stock's rise snapped a three-day losing streak.
23h
Zacks Investment Research on MSNHere is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending StockMerck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the ...
We recently published a list of 10 Dirt Cheap Stocks To Invest In Now. In this article, we are going to take a look at where ...
Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the ...
Merck signs deal with Austria's Cyprumed to develop oral peptide therapies, potentially paying up to $493 million for access ...
Guggenheim analyst Vamil Divan maintained a Buy rating on Merck & Company (MRK – Research Report) today and set a price target of ...
Drugmaker Novartis plans to spend $23 billion at 10 of its U.S. facilities, as the pharma industry grapples with Trump’s ...
Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for a novel medicine.Most ...
Shares of Merck & Co. Inc. MRK slid 2.46% to $76.46 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to 5,275.70 and ...
Michelle Xia represents a rising generation of biotech companies in China challenging Western giants.
In this article, we are going to take a look at where Merck & Co. Inc. (NYSE:MRK) stands against other high growth forever dividend stocks. Dividend stocks have trailed the broader market over the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results